SBC Medical Group Holdings stock
SBCNASDAQSBC Medical Group Holdings Incorporated, IndustrialsISIN US73245B1070
77Score 77 out of 100, Strong
Price and trend
79 / 100
Price history
+58% in one yearThe chart shows daily closes over 4 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 35% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 51).
The price is 6.2% below its 52-week high. Largest decline in 4 years: 82% (August 2024 to May 2026).
Chart figures for advanced users
- SMA 50$5.07
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.95
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)51
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.87
- The lowest closing price of the last twelve months.
- Resistance$5.69
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- SBC Medical Group Holdings Incorporated belongs to the Consulting Services industry (United States) and, with a market value of $549.2M, is number 12 of 16 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $173.61M (down 15.5% year on year) and earnings of $50.99M (up 9.4%).
- For fiscal 2026, analysts expect on average revenue of $190.97M (up 10%) and adjusted earnings per share of $0.46 (down 6.4%).
Show more
- MEQIRI Score 77 out of 100 (Strong): rank 38 of 1023 in Industrials, median 61.
- The P/E is 11.2 (Consulting Services median 23.5, own median of recent years 18.6).
- Our model puts fair value at $9.38, with the price 44% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 36% in fiscal 2025, Consulting Services median 9.5%.Profitability 93
- Modestly valuedP/E 11.2, Consulting Services median 23.5, own median 18.6.Valuation 85
- Below fair valuePrice 44% below the fair value of $9.38.Valuation 85
Weaknesses
- Volatile share priceVolatility 55% a year over the last 12 months.
Its standout strengths are fundamentals and profitability, while growth holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $6.70 and expensive above $15.64 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $7.54 (cash-flow model) and $11.23 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $8.75, at 7.8% it would be $10.33.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (23.5).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 6.9% on the twelve months before. Revenue has stayed largely stable since 2022.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 73%, operating 39%, net 29%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 13 Nov 2026tomorrow
- Last reported
- 13 Aug 2026EPS reported $0.10 (expected $0.12)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.460.0%
- Revenue
- $190.97M0.0%
- Earnings per share
- $0.520.0%
- Revenue
- $206.26M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +14.4%Strong growth is still expected and the call center and clinic support are expected to add about $15 million per year together, with no specific guidance or comparison to before.
“Enhanced call center functions are expected to add roughly $11 million per year and stronger support for the Gorilla and Rize Clinic is expected to add roughly $4 million, together, about $15 million per year on a full year basis.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Aikawa YoshiyukiSale
28 Apr 2026, 10 percent owner, officer: Chairman and CEO
- Shares
- 465,000
- Price
- $3.02
- Value
- $1.41M
- Aikawa YoshiyukiSale
21 Apr 2026, 10 percent owner, officer: Chairman and CEO
- Shares
- 3,100,000
- Price
- $3.02
- Value
- $9.37M
- Aikawa YoshiyukiSale
6 Mar 2026, 10 percent owner, officer: Chairman and CEO
- Shares
- 4,422,900
- Price
- $2.12
- Value
- $9.38M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at SBC Medical Group Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
1023 rated companies in Industrials
- This company
- 77
- Sector median
- 61
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Consulting Services
The next larger and next smaller companies by market value
- Huron Consulting GroupHURN $2.65B64
- IpsosIPS.PA $1.67B67
- ICF InternationalICFI $1.49B64
- CRA InternationalCRAI $1.26B70
- BTS GroupBTS-B.ST $509.71M72
- Enento GroupENENTO.HE $430.98M60
- Roma Green FinanceROMA $335.4M34
- RejlersREJL-B.ST $323.28M51
ETFs that hold SBC Medical Group Holdings
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.00% | 0.30% | €2.17B |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.00% | 0.39% | €1.47B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 14 Aug 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.